Valuation: Orexo AB

Market Cap 856M 88.08M 77.23M 71.18M 66.64M 125M 8.31B 128M 331M 4.11B 331M 324M 14.24B P/E 2026 *
-2.71x
P/E 2027 * -3.4x
Enterprise Value 658M 67.69M 59.35M 54.71M 51.22M 96.05M 6.39B 98.04M 254M 3.16B 254M 249M 10.94B EV / Sales 2026 *
25.3x
EV / Sales 2027 * 26.4x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day-6.25%
3 months-8.14%
6 months-34.98%
Current year-34.98%
Current year 2.1
Extreme 2.1
2.29
1 year 2.02
Extreme 2.02
3.23
3 years 1.08
Extreme 1.08
3.23
5 years 1.04
Extreme 1.04
4.13
10 years 1.04
Extreme 1.04
7.7
Manager TitleAgeSince
Chief Executive Officer 54 04/02/2013
Director of Finance/CFO 59 31/08/2022
Chief Tech/Sci/R&D Officer - 30/09/2024
Director TitleAgeSince
Director/Board Member 64 31/12/2001
Director/Board Member 70 10/04/2019
Director/Board Member 62 31/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-.--% - - 88.08M
+2.56%+12.99%+63.21%+13.78% 318B
-0.92%+9.59%+30.45%-4.55% 72.22B
+3.20%+9.35%+42.70%+115.15% 8.89B
-0.43%+0.43%+2.99%-6.70% 8.25B
-6.43%-4.71%-9.79%-0.60% 4.23B
-6.42%+5.27%+2.08%+22.34% 3.58B
-6.87%-12.75%-34.90%+19.59% 3.23B
+4.67%+5.54%+50.13%+54.13% 2.72B
-4.41%+5.98%+9.57%-22.65% 2.03B
Average -2.13%+2.78%+17.38%+21.17% 46.99B
Weighted average by Cap. +1.66%+11.47%+53.67%+12.44%

Financials

2026 *2027 *
Net sales 26M 2.68M 2.35M 2.16M 2.03M 3.8M 252M 3.88M 10.06M 125M 10.05M 9.83M 433M 27M 2.78M 2.44M 2.25M 2.1M 3.94M 262M 4.03M 10.45M 130M 10.44M 10.21M 449M
Net income -322M -33.15M -29.06M -26.79M -25.08M -47.03M -3.13B -48.01M -125M -1.55B -124M -122M -5.36B -259M -26.66M -23.38M -21.55M -20.17M -37.83M -2.52B -38.62M -100M -1.24B -100M -97.93M -4.31B
Net Debt -198M -20.38M -17.87M -16.47M -15.42M -28.92M -1.92B -29.52M -76.61M -950M -76.54M -74.87M -3.3B -142M -14.62M -12.82M -11.81M -11.06M -20.74M -1.38B -21.17M -54.95M -682M -54.89M -53.69M -2.36B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
65
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise